- Previous Close
0.4100 - Open
0.4150 - Bid 0.4000 x --
- Ask 0.4150 x --
- Day's Range
0.4100 - 0.4150 - 52 Week Range
0.3450 - 0.8000 - Volume
28,123 - Avg. Volume
109,068 - Market Cap (intraday)
46.284M - Beta (5Y Monthly) 1.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Feb 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.42
INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
www.inoviq.comRecent News: IIQ.AX
View MorePerformance Overview: IIQ.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IIQ.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IIQ.AX
View MoreValuation Measures
Market Cap
46.28M
Enterprise Value
37.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
71.68
Price/Book (mrq)
2.37
Enterprise Value/Revenue
69.24
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.43%
Return on Equity (ttm)
-39.07%
Revenue (ttm)
1.69M
Net Income Avi to Common (ttm)
-7.08M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
9.48M
Total Debt/Equity (mrq)
1.25%
Levered Free Cash Flow (ttm)
-2.64M